{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:35Z","timestamp":1790270975253,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01541-9","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T03:53:23Z","timestamp":1757649203000},"page":"3195-3212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic Literature Reviews on the Disease Burden of Pediatric Psoriasis"],"prefix":"10.1007","volume":"15","author":[{"given":"Santiago Zuluaga","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffanie","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshnavi","family":"Telukuntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Deignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"1541_CR1","unstructured":"National Psoriasis Foundation. Psoriasis Statistics. 2022 May 13, 2025]; Available from: https:\/\/www.psoriasis.org\/content\/statistics."},{"issue":"8","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","volume":"12","author":"K Peris","year":"2022","unstructured":"Peris K, et\u00a0al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753\u201375.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1541_CR3","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s13555-022-00761-7","volume":"12","author":"M Sticherling","year":"2022","unstructured":"Sticherling M, et\u00a0al. Patient characteristics and treatment patterns in European pediatric patients with psoriasis: a real-world, cross-sectional study. Dermatol Ther (Heidelb). 2022;12(8):1793\u2013808.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1541_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.944208","volume":"9","author":"K Golhen","year":"2022","unstructured":"Golhen K, et\u00a0al. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. Front Med (Lausanne). 2022;9:944208.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1541_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, et\u00a0al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1541_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1529-8019.2006.00058.x","volume":"19","author":"A Krol","year":"2006","unstructured":"Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther. 2006;19(2):73\u201382.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1440-0960.2012.00878.x","volume":"53","author":"S Kapila","year":"2012","unstructured":"Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis. Australas J Dermatol. 2012;53(2):98\u2013105.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1541_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, et\u00a0al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373\u201384.","journal-title":"Paediatr Drugs"},{"key":"1541_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911128","author":"F Diotallevi","year":"2022","unstructured":"Diotallevi F, et\u00a0al. Biological treatments for pediatric psoriasis: state of the art and future perspectives. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911128.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1541_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ad.2023.02.017","volume":"114","author":"R de Lucas","year":"2023","unstructured":"de Lucas R, et\u00a0al. Clinical unmet needs and treatment patterns of paediatric psoriasis patients: a real-world evidence study in Spain. Actas Dermo-Sifiliogr. 2023;114(5):382\u201391.","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"1","key":"1541_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2339440","volume":"35","author":"SD Smith","year":"2024","unstructured":"Smith SD, et\u00a0al. Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia. J Dermatolog Treat. 2024;35(1):2339440.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1541_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253048","volume":"16","author":"E Duncanson","year":"2021","unstructured":"Duncanson E, et\u00a0al. The prevalence and evidence-based management of needle fear in adults with chronic disease: a scoping review. PLoS ONE. 2021;16(6):e0253048.","journal-title":"PLoS ONE"},{"issue":"2","key":"1541_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s13555-016-0117-6","volume":"6","author":"M Napolitano","year":"2016","unstructured":"Napolitano M, et\u00a0al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther (Heidelb). 2016;6(2):125\u201342.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1541_CR14","unstructured":"Higgins, J., et\u00a0al., Cochrane Handbook for Systematic Reviews of Interventions, version 6.5. 2024: Cochrane."},{"key":"1541_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"7052","key":"1541_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO, The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"issue":"4","key":"1541_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jval.2013.02.017","volume":"16","author":"D Papaioannou","year":"2013","unstructured":"Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health. 2013;16(4):686\u201395.","journal-title":"Value Health"},{"key":"1541_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.zefq.2023.10.004","volume":"182\u2013183","author":"M Biermann","year":"2023","unstructured":"Biermann M, Kolb B. Epidemiology, comorbidity, and use of systemic therapies in patients with paediatric psoriasis in Germany. Z Evid Fortbild Qual Gesundhwes. 2023;182\u2013183:1\u20137.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"9","key":"1541_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/03007995.2023.2243216","volume":"39","author":"F Lapi","year":"2023","unstructured":"Lapi F, et\u00a0al. Epidemiology of pediatric psoriasis: a population-based study using two Italian data sources. Curr Med Res Opin. 2023;39(9):1257\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000381913","volume":"231","author":"M Augustin","year":"2015","unstructured":"Augustin M, et\u00a0al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35\u201340.","journal-title":"Dermatology"},{"issue":"4","key":"1541_CR21","first-page":"473","volume":"153","author":"P Toscano","year":"2018","unstructured":"Toscano P, et\u00a0al. Childhood psoriasis: a survey among pediatricians in Italy. G Ital Dermatol Venereol. 2018;153(4):473\u20136.","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"1541_CR22","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, et\u00a0al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187\u201394.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1541_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/1346-8138.16996","volume":"51","author":"TL Lin","year":"2024","unstructured":"Lin TL, et\u00a0al. The epidemiology of pediatric psoriasis: a nationwide cohort study in Taiwan. J Dermatol. 2024;51(1):48\u201355.","journal-title":"J Dermatol"},{"issue":"10","key":"1541_CR24","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3879","volume":"101","author":"R Maximilian","year":"2021","unstructured":"Maximilian R, et\u00a0al. Epidemiology, comorbidity and risk factors for psoriatic arthritis: a health insurance claims database analysis. Acta Derm Venereol. 2021;101(10):adv00566.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1541_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.23736\/S0392-0488.18.06020-0","volume":"155","author":"F Valent","year":"2020","unstructured":"Valent F, et\u00a0al. The epidemiology of psoriasis in an Italian area: population-based analysis of administrative data. G Ital Dermatol Venereol. 2020;155(5):652\u20137.","journal-title":"G Ital Dermatol Venereol"},{"issue":"5","key":"1541_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","volume":"158","author":"AS Paller","year":"2022","unstructured":"Paller AS, et\u00a0al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patientswith moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533\u201341.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1541_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00403-023-02796-y","volume":"316","author":"M Deike","year":"2024","unstructured":"Deike M, et\u00a0al. Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population. Arch Dermatol Res. 2024;316(2):65.","journal-title":"Arch Dermatol Res"},{"key":"1541_CR28","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1962","volume":"102","author":"IYK Iskandar","year":"2022","unstructured":"Iskandar IYK, et\u00a0al. Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in Taiwan: a nationwide cohort study. Acta Derm Venereol. 2022;102:adv00807.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"1541_CR29","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/ced.14713","volume":"46","author":"C Lecaros","year":"2021","unstructured":"Lecaros C, et\u00a0al. The incidence of psoriasis in Chile: an analysis of the national waiting list repository. Clin Exp Dermatol. 2021;46(7):1262\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"1541_CR30","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/jdv.15762","volume":"33","author":"Y Schonmann","year":"2019","unstructured":"Schonmann Y, et\u00a0al. Incidence and prevalence of psoriasis in Israel between 2011 and 2017. J Eur Acad Dermatol Venereol. 2019;33(11):2075\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1541_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1684\/ejd.2014.2291","volume":"24","author":"T Torres","year":"2014","unstructured":"Torres T, et\u00a0al. Cardiovascular comorbidities in childhood psoriasis. Eur J Dermatol. 2014;24(2):229\u201335.","journal-title":"Eur J Dermatol"},{"issue":"12","key":"1541_CR32","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamadermatol.2016.3432","volume":"152","author":"A Lee","year":"2016","unstructured":"Lee A, et\u00a0al. Association between pediatric psoriasis and waist-to-height ratio in the absence of obesity: a multicenter Australian study. JAMA Dermatol. 2016;152(12):1314\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1541_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/2475530318799072","volume":"3","author":"TG Brandon","year":"2018","unstructured":"Brandon TG, et\u00a0al. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J Psoriasis Psoriatic Arthritis. 2018;3(4):131\u20136.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"5","key":"1541_CR34","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1111\/pde.13539","volume":"35","author":"MK Hunjan","year":"2018","unstructured":"Hunjan MK, et\u00a0al. Association between obesity and pediatric psoriasis. Pediatr Dermatol. 2018;35(5):e304\u20135.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1541_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/jamadermatol.2017.5417","volume":"154","author":"MM Tollefson","year":"2018","unstructured":"Tollefson MM, et\u00a0al. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol. 2018;154(3):286\u201392.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1541_CR36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/alr.22429","volume":"9","author":"SY Kim","year":"2019","unstructured":"Kim SY, et\u00a0al. Increased risk of psoriasis in children and elderly patients with asthma: a longitudinal follow-up study using a national sample cohort. Int Forum Allergy Rhinol. 2019;9(11):1304\u201310.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"1541_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2340\/00015555-1986","volume":"95","author":"J Lysell","year":"2015","unstructured":"Lysell J, et\u00a0al. Clinical characterisation at onset of childhood psoriasis-a cross sectional study in Sweden. Acta Derm Venereol. 2015;95(4):457\u201361.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1541_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/JID.2015.385","volume":"136","author":"WL Tom","year":"2016","unstructured":"Tom WL, et\u00a0al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. J Invest Dermatol. 2016;136(1):67\u201373.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1541_CR39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaad.2017.08.034","volume":"77","author":"L Kwa","year":"2017","unstructured":"Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States. J Am Acad Dermatol. 2017;77(6):1023\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1541_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/pde.15429","volume":"40","author":"B Roman","year":"2023","unstructured":"Roman B, et\u00a0al. Black and male children have an increased risk of palmoplantar psoriasis compared to white children. Pediatr Dermatol. 2023;40(6):1071\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"1541_CR41","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/bjd.13507","volume":"172","author":"E Mah\u00e9","year":"2015","unstructured":"Mah\u00e9 E, et\u00a0al. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol. 2015;172(6):1593\u2013600.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1541_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.annder.2016.02.006","volume":"143","author":"J Bonigen","year":"2016","unstructured":"Bonigen J, et\u00a0al. Impact of sex and age on the clinical and epidemiological aspects of childhood psoriasis: data from a French cross-sectional multicentre study. Ann Dermatol Venereol. 2016;143(5):354\u201363.","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"1541_CR43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.annder.2019.01.024","volume":"146","author":"E Mahe","year":"2019","unstructured":"Mahe E, et\u00a0al. Children with psoriasis in secondary care: clinical aspects and comorbidities diverge from the generally published data. Ann Dermatol Venereol. 2019;146(5):354\u201362.","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"1541_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamadermatol.2014.324","volume":"150","author":"L Becker","year":"2014","unstructured":"Becker L, et\u00a0al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573\u20134.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1541_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00592-017-1000-3","volume":"54","author":"L Di Costanzo","year":"2017","unstructured":"Di Costanzo L, et\u00a0al. Psoriasis in children with type 1 diabetes: a new comorbidity to be considered? Acta Diabetol. 2017;54(8):803\u20134.","journal-title":"Acta Diabetol"},{"issue":"7","key":"1541_CR46","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1007\/s12325-021-01795-7","volume":"38","author":"E Edson-Heredia","year":"2021","unstructured":"Edson-Heredia E, et\u00a0al. Real-world claims analyses of comorbidity burden, treatment pattern, healthcare resource utilization, and costs in pediatric psoriasis. Adv Ther. 2021;38(7):3948\u201361.","journal-title":"Adv Ther"},{"issue":"3","key":"1541_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/pde.13772","volume":"36","author":"AS Paller","year":"2019","unstructured":"Paller AS, et\u00a0al. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290\u20137.","journal-title":"Pediatr Dermatol"},{"key":"1541_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, et\u00a0al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231\u201341.","journal-title":"Br J Dermatol"},{"key":"1541_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","volume":"86","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, et\u00a0al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86:122\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"1541_CR50","unstructured":"Seyger M, A.M., Sticherling M et\u00a0al., Healthcare resource utilization among paediatric patients with psoriasis based on realworld data from the EU5 and US. IFPA, 2021."},{"key":"1541_CR51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjd.19747","volume":"185","author":"H Hamm","year":"2021","unstructured":"Hamm H, Wilsmann-Theis D, Tsianakas A, Gambichler T, Taipale K, Lauterbach J, et\u00a0al. Efficacy and safety of fumaric acid esters in young patients aged 10\u201317 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Br J Dermatol. 2021;185:62\u201373.","journal-title":"Br J Dermatol"},{"key":"1541_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/pde.14403","volume":"38","author":"S Mannix","year":"2021","unstructured":"Mannix S, et\u00a0al. The experience of itch in children with psoriasis: a qualitative exploration of the itch numeric rating scale. Pediatr Dermatol. 2021;38:405\u201312.","journal-title":"Pediatr Dermatol"},{"key":"1541_CR53","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.2544","author":"MMB Seyger","year":"2023","unstructured":"Seyger MMB, et\u00a0al. Patient-reported outcomes and burden of disease in paediatric patients with psoriasis: real-world data from EU5 and US. Acta Dermato-Venereol. 2023. https:\/\/doi.org\/10.2340\/actadv.v103.2544.","journal-title":"Acta Dermato-Venereol"},{"key":"1541_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/pde.13585","volume":"35","author":"B Tekin","year":"2018","unstructured":"Tekin B, et\u00a0al. Assessment of quality of life in Turkish children with psoriasis and their caregivers. Pediatr Dermatol. 2018;35:651\u20139.","journal-title":"Pediatr Dermatol"},{"key":"1541_CR55","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/pde.15297","volume":"40","author":"A Horev","year":"2023","unstructured":"Horev A, et\u00a0al. Pediatric psoriasis negatively influences parental sleep quality. Pediatr Dermatol. 2023;40:610\u20134.","journal-title":"Pediatr Dermatol"},{"key":"1541_CR56","first-page":"1743","volume":"35","author":"NL Bragazzi","year":"2021","unstructured":"Bragazzi NL, et\u00a0al. Sleep quality in parents with children affected by psoriasis, psoriatic arthritis or atopic dermatitis: a multicenter cross-sectional study. J Biol Regul Homeost Agents. 2021;35:1743\u201353.","journal-title":"J Biol Regul Homeost Agents"},{"key":"1541_CR57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40257-017-0318-5","volume":"19","author":"S Moawad","year":"2018","unstructured":"Moawad S, et\u00a0al. Topical corticosteroid concerns among parents of children with psoriasis versus atopic dermatitis: a French multicenter cross-sectional study. Am J Clin Dermatol. 2018;19:261\u20135.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1541_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000499564","volume":"235","author":"KR Patel","year":"2019","unstructured":"Patel KR, et\u00a0al. Association of psoriasis with psychiatric hospitalization in United States children and adults. Dermatology. 2019;235(4):276\u201386.","journal-title":"Dermatology"},{"key":"1541_CR59","unstructured":"Gemeinsamer Bundesausschuss. [Benefit assessment method for the active ingredient ixekizumab (New indication: plaque psoriasis in children and adolescents \u2265 6 to < 18 years, body weight \u2265 25 kg)]. 2021 May 13, 2025]; Available from: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/569\/."},{"key":"1541_CR60","unstructured":"Gemeinsamer Bundesausschuss. [Benefit assessment method for the active ingredient secukinumab (New indication: plaque psoriasis, \u2265 6 to < 18 years)]. 2021 May 13, 2025]; Available from: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/591\/."},{"issue":"1","key":"1541_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1046\/j.1468-3083.2001.00192.x","volume":"15","author":"SP Raychaudhuri","year":"2001","unstructured":"Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1541_CR62","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamapediatrics.2024.1576","volume":"178","author":"X Zhang","year":"2024","unstructured":"Zhang X, et\u00a0al. Global prevalence of overweight and obesity in children and adolescents: a systematic review and meta-analysis. JAMA Pediatr. 2024;178(8):800\u201313.","journal-title":"JAMA Pediatr"},{"issue":"6","key":"1541_CR63","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01541-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01541-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01541-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:02:48Z","timestamp":1761242568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01541-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01541-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Santiago Zuluaga Sanchez, Tiffanie Tran, and Cynthia Deignan are employees of, and own stock in, Amgen Inc., which funded this study. Andrea Garcia, Vyshnavi Telukuntla, Sumi Pillai, and Jake Horgan are employees of Lumanity Inc., who received funding from Amgen Inc. for the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}